Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 94, Issue 1, 2011, Pages 22-32

  Petrica, Ligia ^a   Vlad, A ^a   Petrica, M ^a   Jianu, C D ^a   Gluhovschi, Gh ^a   Gadalean, Florica ^a   Dumitrascu, V ^a   Ianculescu, Calina ^a   Firescu, Catalina ^a   Giju, S ^a   Gluhovschi, Cristina ^a   Bob, F ^a   Velciov, Silvia ^a   Bozdog, Gh ^a   Milas, Oana ^a   Marian, Roxana ^a   Ursoniu, S ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Albuminuria; Endothelial dysfunction; Pioglitazone; Proximal tubule

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; N(G),N(G) DIMETHYLARGININE; PIOGLITAZONE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BRAIN PROTECTION; BREATH HOLDING; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR DISEASE; CEREBROVASCULAR REACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTERNAL CAROTID ARTERY; INTIMA MEDIA THICKNESS; KIDNEY PROXIMAL TUBULE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PULSATILITY INDEX; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RESISTANCE INDEX; VASCULAR ENDOTHELIUM;

ALBUMINURIA; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 80054903824     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.05.032     Document Type: Article

References (57)

1. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons, in 2007 Annual data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, p. 239-54.
2. Schernthaner G. Kidney disease in diabetology: lessons from 2010. Nephrol Dial Transplant 2011, 26:454-457.
3. Rocco A., Heerlein K., Diedler J., Sykora M., Barrows R., Hacke W., et al. Microalbuminuria in cerebrovascular disease: a modifiable risk factor?. Int J Stroke 2010, 5:30-34.
4. Knopman D.S. Invited commentary: albuminuria and microvascular disease of the brain - a shared pathophysiology. Am J Epidemiol 2010, 171:287-289.
5. Lim S.C., Caballero A.E., Smakowski P., LoGerfo F.W., Horton E.S., Veves A. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 1999, 22:1865-1870.
6. Comper W.D., Haraldsson B., Deen W.M. Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 2008, 19:427-432.
7. Russo L.M., Sandoval R.M., Campos S.B., Molitoris B.A., Comper W.D., Brown D. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009, 20:489-494.
8. Petrica L., Petrica M., Vlad A., Jianu D.C., Gluhovschi G., Ianculescu C., et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 2009, 121:765-775.
9. Petrica L., Petrica M., Vlad A., Jianu D.C., Gluhovschi Gh, Ianculescu C., et al. Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study. Nephron Clin Pract 2011, 118:c155-c164.
10. Wilcox R., Kupfer S., Erdmann E. PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008, 155:712-717.
11. Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010, 55:835-847.
12. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Task force members. Guidelines on diabetes and cardiovascular disease of the European association for the study of diabetes (EASD). Eur Heart J 2007, 28:88-136.
13. Levey A.S., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2098-2100.
14. Valdueza J.M., Schreiber S.J., Roehl J.E., Klingebiel R. Neurosonology and neuroimaging of stroke 2008, Georg Thieme Verlag, Stuttgart.
15. Widder B. Use of breath holding for evaluating cerebrovascular reserve capacity. Stroke 1992, 23:1680-1689.
16. Nakagawa T., Tanabe K., Croker B.P., Johnson R.J., Grant M.B., Kosugi T., et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 2011, 7:36-44.
17. Fioretto P., Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007, 27:195-207.
18. Stehouwer C.D., Gall M.A., Twisk J.W., Knudsen E., Emeis J.J., Parving H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002, 51:1157-1165.
19. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004, 27:765-769.
20. Altinova A.E., Arslan M., Sepici-Dincel A., Akturk M., Altan N., Toruner F.B. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007, 92:1881-1885.
21. Hanai K., Babazono T., Nyumura I., Toya K., Tanaka N., Tanaka M., et al. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2009, 24:1884-1888.
22. Konukoglu D., Firtina S., Serin O. The relationship between plasma asymmetrical dimethyl-l-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism 2008, 57:110-115.
23. Shibata R., Ueda S., Yamagishi S., Kaida Y., Matsumoto Y., Fukami K., et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrol Dial Transplant 2009, 24:1162-1169.
24. Kralik P.M., Long Y., Song Y., Yang L., Wei H., Coventry S., et al. Diabetic albuminuria is due to a small fraction of nephrons distinguished by albumin-stained tubules and glomerular adhesions. Am J Pathol 2009, 175:500-509.
25. Korpinen E., Teppo A.M., Hukkanen L., Akerblom H.K., Grönhagen-Riska C., Vaarala O. Urinary transforming growth factor-beta1 and alpha1-microglobulin in children and adolescents with type 1 diabetes. Diabetes Care 2000, 23:664-668.
26. Kalansooriya A., Holbrook I., Jennings P., Whiting P.H. Serum cystatin C, enzymuria, tubular proteinuria and early renal insult in type 2 diabetes. Br J Biomed Sci 2007, 64:121-123.
27. Hong C.Y., Hughes K., Chia K.S., Ng V., Ling S.L. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003, 26:338-342.
28. Vaidya V.S., Niewczas M.A., Ficociello L.H., Johnson A.C., Collings F.B., Warram J.H., et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-d-glucosaminidase. Kidney Int 2011, 79:464-470.
29. Wakino S., Hayashi K., Tatematsu S., Hasegawa K., Takamatsu I., Kanda T., et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005, 28:255-262.
30. Schernthaner G., Matthews D.R., Charbonnel B., Hanefeld M., Brunetti P. Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004, 89:6068-6076.
31. Perkins B.A., Ficociello L.H., Roshan B., Warram J.H., Krolewski A.S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77:57-64.
32. Jerums G., Panagiotopoulos S., Premaratne E., MacIsaac R.J. Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol 2009, 5:397-406.
33. Ninomiya T., Perkovic V., de Galan B.E., Zoungas S., Pillai A., Jardine M., et al. ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821.
34. Middleton R.J., Foley R.N., Hegarty J., Cheung C.M., McElduff P., Gibson J.M., et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006, 21:88-92.
35. Ritz E., Viberti G.C., Ruilope L.M., Rabelink A.J., Izzo J.L., Katayama S., et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010, 53:49-57.
36. Touboul P.J., Elbaz A., Koller C., Lucas C., Adraï V., Chédru F., et al. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC) case-control study. The GENIC Investigators. Circulation 2000, 102:313-318.
37. Kanazawa I., Yano S., Notsu Y., Yamaguchi T., Nabika T., Sugimoto T. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2011, 74:467-472.
38. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.
39. Yamasaki Y., Katakami N., Furukado S., Kitagawa K., Nagatsuka K., Kashiwagi A., et al. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb 2010, 17:1132-1140.
40. Langenfeld M.R., Forst T., Hohberg C., Kann P., Lübben G., Pfützner A., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005, 111:2525-2531.
41. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008, 24:14-26.
42. Ito H., Komatsu Y., Mifune M., Antoku S., Ishida H., Takeuchi Y., et al. The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol 2010, 9:18-28.
43. Nakamura T., Matsuda T., Kawagoe Y., Ogawa H., Takahashi Y., Sekizuka K., et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004, 53:1382-1386.
44. Faraci F.M. Protecting the brain with eNOS: run for your life. Circ Res 2006, 99:1029-1030.
45. Iadecola C., Pelligrino D.A., Moskowitz M.A., Lassen N.A. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 1994, 14:175-192.
46. Tkac I., Troscak M., Javorsky M., Petrik R., Tomcova M. Increased intracranial arterial resistance in patients with type 2 diabetes mellitus. Wien Klin Wochenschr 2001, 113:870-873.
47. Lee K.Y., Young H.S., Baik J.S., Kim G.W., Kim J.S. Arterial pulsatility as an index of cerebral microangiopathy in diabetes. Stroke 2000, 31:1111-1115.
48. Petrica L., Petrica M., Munteanu M., Vlad A., Bob F., Gluhovschi C., et al. Cerebral microangiopathy in patients with non-insulin-dependent diabetes mellitus. Ann Acad Med Singapore 2007, 36:259-266.
49. Park J.S., Cho M.H., Lee K.Y., Kim C.S., Kim H.J., Nam J.S., et al. The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus. Metabolism 2007, 56:1081-1086.
50. Fulesdi B., Limburg M., Bereczki D., Kaplar M., Molnar C., Kappelmayer J., et al. Cerebrovascular reactivity and reserve capacity in type II diabetes mellitus. J Diabet Complications 1999, 13:191-199.
51. Kadoi Y., Hinohara H., Kunimoto F., Saito S., Ide M., Hiraoka H., et al. Diabetic patients have an impaired cerebral vasodilatory response to hypercapnia under propofol anesthesia. Stroke 2003, 34:2399-2403.
52. Petrica L., Petrica M., Vlad A., Bob F., Gluhovschi C., Gluhovschi Gh., et al. Cerebrovascular reactivity is impaired in patients with non-insulin-dependent diabetes mellitus and microangiopathy. Wien Klin Wochenschr 2007, 119(11-12):365-371.
53. 2 vasoreactivity: association with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2006, 291:H1856-H1861.
54. Kozera G.M., Wolnik B., Kunicka K.B., Szczyrba S., Wojczal J., Schminke U., et al. Cerebrovascular reactivity, intima-media thickness, and nephropathy presence in patients with type 1 diabetes. Diabetes Care 2009, 32:878-882.
55. Papathanassiou K., Naka K.K., Kazakos N., Kanioglou C., Makriyiannis D., Pappas K., et al. Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 2009, 205:221-226.
56. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney Int 2004, 66(Suppl. 92):S2-S6.
57. Wang T.J., Evans J.C., Meigs J.B., Rifai N., Fox C.S., D'Agostino R.B., et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005, 111:1370-1376.